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CORRESPONDENCE

Letters to the Editor

Ranolazine Is Effective
for Acute or Chronic Ischemic
Dysfunction With Heart Failure
We congratulate Morrow et al. (1) for their interesting study on the effects
of ranolazine in patients with non–ST-segment elevation myocardial
infarction. Ranolazine reduced the composite primary end point of
cardiovascular death, myocardial infarction, and recurrent ischemia in
patients with B-type natriuretic peptide ⬎80 pg/ml. Interestingly, there
was a decrease in composite arrhythmia end points consisting of ventricular tachycardia (⬎100 beats/min for ⬎3 beats), supraventricular tachycardia (⬎120 beats/min for ⬎4 beats), and bradycardia (⬍40 beats/min,
pause ⬎2.5 s or 3o atrioventricular block). Ranolazine usage showed a
trend toward reduction across all arrhythmia types: ventricular tachycardia
(p ⫽ 0.13), supraventricular tachycardia (p ⬍ 0.001), atrial fibrillation
(p ⫽ 0.4), and sudden cardiac death (p ⫽ 0.11). These effects were
observed over a mean duration of 343 days.
We recently reported successful use of ranolazine in a patient with
chronic ischemic cardiomyopathy, symptomatic premature ventricular
complexes (PVC [⬎36% of all beats]), and monomorphic ventricular
tachycardia who had failed amiodarone and mexilitine therapy.
Ranolazine decreased the total number of PVCs to 1% to 2% of all
beats, eliminated the ventricular tachycardia, and led to complete
resolution of symptoms (2).
Inhibition of the late sodium current (INa) is the proposed
mechanism of both the anti-ischemic and anti-arrhythmic benefits of
ranolazine. Activity in late INa activity is increased significantly in
ischemia as well as congestive heart failure (3). Increased late INa
activity produces higher intracellular sodium, which results in calcium
overload through the sodium-calcium exchange. Ranolazine inhibits
late INa 10-fold more selectively than peak INa. This mechanism,
along with its ␤1, ␤2, and calcium-channel antagonism, produces its
anti-ischemic and antiarrhythmic benefits (3).
The present study shows beneficial effects of ranolazine in the setting
of acute ischemia with evidence of heart failure. Our patient had a chronic
ischemic cardiomyopathy with severe myocardial dysfunction (ejection
fraction 15%) for which ranolazine produced excellent symptomatic relief.
Future studies using ranolazine are needed to evaluate patients with acute
and chronic ischemia in the presence of elevated B-type natriuretic
peptide/left ventricular dysfunction to further clarify its benefits. It
may be this category of patients who have the highest risk– benefit
ratio from ranolazine therapy.
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Reply
We appreciate the compliment and additional perspective from
Dr. Nanda and colleagues regarding our paper (1). Patients with
ischemic heart disease and left ventricular dysfunction, such as the
patient described by Dr. Nanda and colleagues, are at substantial
risk of major cardiovascular events, including sudden cardiac death.
Moreover, they are at higher risk of proarrhythmia than patients
with normal left ventricular function with multiple classes of
antiarrhythmic medications, and they may poorly tolerate antiischemic medications with negative inotropic effects. We have also
observed that patients with elevated levels of B-type natriuretic
peptide are at particularly high risk of sudden cardiac death, even
after accounting for left ventricular ejection fraction (2).
In pre-clinical studies, ranolazine has shown potentially favorable electrophysiological effects, such as a decrease in dispersion of
repolarization, a reduction in action potential duration, and suppression of early after-depolarizations (3). In addition, in animal
models of heart failure, ranolazine improves contractile function
immediately after acute ischemia (4) and left ventricular ejection
fraction in the setting of chronic ischemic heart failure (5).
We have shown previously that in patients with unstable ischemic
heart disease, ranolazine significantly reduces the risk of ventricular
and supraventricular tachycardia (3). Notably, we have also found that
these effects on arrhythmias are present in patients at higher risk for
tachyarrhythmia, such as those with elevated B-type natriuretic
peptide (1) or a history of left ventricular dysfunction (3). These
findings are consistent with the observations described by Dr. Nanda
and colleagues. On the basis of these collective findings, we agree that
the investigation of ranolazine in patients with ischemic heart disease
and left ventricular dysfunction would be of substantial interest.

Sudip Nanda, MD*
Matthew W. Martinez, MD
Tanujit Dey, PhD

*David A. Morrow, MD, MPH
Benjamin M. Scirica, MD, MPH

*Lehigh Valley Hospital
Cardiovascular Medicine
1240 South Cedar Crest Boulevard
Allentown, Pennsylvania 18103
E-mail: sudipnanda2000@yahoo.com

*TIMI Study Group/Cardiovascular Division
Brigham and Women’s Hospital
75 Francis Street
Boston, Massachusetts 02115
E-mail: dmorrow@partners.org
doi:10.1016/j.jacc.2010.04.039

doi:10.1016/j.jacc.2010.05.027

Downloaded for library services (libraryservices@lvhn.org) at Lehigh Valley Health Network from ClinicalKey.com by Elsevier on
August 26, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

